The importance of screening solid-state phases of a racemic modification of a chiral drug: Thermodynamic and structural characterization of solid-state phases of etiracetam

Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials

Volumn 69, Issue 4, 2013, Pages 371-378

  Herman, Christelle ^a   Vermylen, Valérie ^b   Norberg, Bernadette ^c   Wouters, Johan ^c   Leyssens, Tom ^d  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Formerly Janssen Medical Affairs Europe   (Belgium)

^c UNIVERSITY OF NAMUR   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

(RS) 2 (2 oxo pyrrolidin 1yl) butyramide; etiracetam; levetiracetam; racemic compound; solid state phases

Indexed keywords

BUTYRAMIDE; ETIRACETAM; LEVETIRACETAM; RACEMIC COMPOUNDS; SOLID-STATE PHASIS;

ENANTIOMERS; HYDRATION;

HYDRATES;

DRUG DERIVATIVE; ETIRACETAM; PIRACETAM;

(RS)-2-(2-OXO-PYRROLIDIN-1YL)-BUTYRAMIDE; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; POWDER DIFFRACTION; RACEMIC COMPOUND; SOLID-STATE PHASES; STEREOISOMERISM; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

(RS)-2-(2-OXO-PYRROLIDIN-1YL)-BUTYRAMIDE; ETIRACETAM; LEVETIRACETAM; RACEMIC COMPOUND; SOLID-STATE PHASES;

CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIRACETAM; POWDER DIFFRACTION; STEREOISOMERISM; THERMODYNAMICS;

EID: 84880647604     PISSN: 20525206     EISSN: 20525192     Source Type: Journal    
DOI: 10.1107/S2052519213015054     Document Type: Article

References (23)

1. Admiraal, G., Eikelenboom, J. C. & Vos, A. (1982). Acta Cryst. B38, 2600-2605.
2. Altomare, A., Cascarano, G., Giacovazzo, C. & Guagliardi, A. (1993). J. Appl. Cryst. 26, 343-350.
3. Etter, M. C.,MacDonald, J. C. & Bernstein, J. (1990). Acta Cryst. B46, 256-262.
4. Herman, C., Haut, B., Aerts, L. & Leyssens, T. (2012). Int. J. Pharm. 437, 156-161.
5. Herman, C., Haut, B., Douieb, S., Larcy, A., Vermylen, V. & Leyssens, T. (2012). Org. Process Res. Dev. 16, 49-56.
6. Herman, C., Haut, B., Halloin, V., Vermylen, V. & Leyssens, T. (2011). Org. Process Res. Dev. 15, 774-782.
7. Herman, C., Leyssens, T., Debaste, F. & Haut, B. (2012). J. Cryst. Growth, 342, 57-64.
8. Herman, C., Leyssens, T., Vermylen, V., Halloin, V. & Haut, B. (2011). J. Chem. Thermodyn. 43, 677-682.
9. Herman, C., Leyssens, T., Vermylen, V., Halloin, V. & Haut, B. (2012). J. Therm. Anal. Calorim. 107, 777-788.
10. Hurtado, B., Koepp, M. J., Sander, J. W. & Thompson, P. J. (2006). Epilepsy Behav. 8, 588-592.
11. Isoherranen, N., Yagen, B., Soback, S., Roeder, M., Schurig, V. & Bialer, M. (2001). Epilepsia, 42, 825-830.
12. Kenda, B. M., Matagne, A. C., Talaga, P. E., Pasau, P. M., Differding, E., Lallemand, B. I., Frycia, A. M., Moureau, F. G., Klitgaard, H. V., Gillard, M. R., Fuks, B. & Michel, P. (2004). Med. Chem. 47, 530- 549.
13. Liao, X., Gautam, M., Grill, A. & Zhu, H. J. (2010). J. Pharm. Sci. 99, 246-254.
14. Lyseng-Williamson, K. A. (2011). Epilepsy Drugs, 71, 489-514.
15. Myerson, A. S. (2002). Handbook of Industrial Crystallization. Montvale: Butterworth-Heinemann.
16. Oxford Diffraction (2011). CrysAlis PRO. Oxford Diffraction Ltd, Yarnton, Oxfordshire, England.
17. Picciochi, R., Diogo, H. P. & da Piedade, M. E. (2011). J. Pharm. Sci. 100, 594-603.
18. Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.
19. Song, J., Lou, K.-X., Li, X.-J., Wu, X.-. & Feng, R.-X. (2003). Acta Cryst. E59, o1772-o1773.
20. Springuel, G. & Leyssens, T. (2012). Cryst. Growth Des. 12, 3374- 3378.
21. Springuel, G., Norberg, B., Robeyns, K., Wouters, J. & Leyssens, T. (2012). Cryst. Growth Des. 12, 475-484.
22. Viertelhaus, S., Hilfiker, R. & Blatter, F. (2009). Cryst. Growth Des. 9, 2220-2228.
23. Vishweshwar, P., McMahon, J. A., Peterson, M. L., Hickey, M. B., Shattock, T. R. & Zaworotko, M. J. (2005). Chem. Commun. pp. 4601-4603.